Targeted Therapy in Indolent Lymphoma
This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Discuss the safety and efficacy of novel targeted therapies in the management of patients with indolent NHLs
Jeremy S. Abramson, MD
Massachusetts General Hospital Cancer Center
- 0.50 Participation
- 0.52 Nurse
- 0.50 Pharmacist
- 0.50 Physician